Roche reported an in line performance in Q1, although it reported only the top-line numbers. Group sales grew by 4% (vs 3% in both Q3 and Q4 16) at CER to CHF12.9bn, with the pharma business growing by 3% to CHF10.2bn and diagnostics by 6% to CHF2.8bn. All revenue growth numbers are in CER unless mentioned otherwise. The US market (+6%) contributed 94% of this growth while Japan languished at 2%, and Europe and International markets barely managed 1% growth. The highlight of the quarter was T
01 May 2017
Strong quarter, no major surprises
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong quarter, no major surprises
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
01 May 2017 -
Author:
Kamla Singh -
Pages:
3
Roche reported an in line performance in Q1, although it reported only the top-line numbers. Group sales grew by 4% (vs 3% in both Q3 and Q4 16) at CER to CHF12.9bn, with the pharma business growing by 3% to CHF10.2bn and diagnostics by 6% to CHF2.8bn. All revenue growth numbers are in CER unless mentioned otherwise. The US market (+6%) contributed 94% of this growth while Japan languished at 2%, and Europe and International markets barely managed 1% growth. The highlight of the quarter was T